ERBB2 and breast carcinoma: Triple-negative, metastatic MDA-MB-231 cells were chosen as representatives of basal B (claudin-low, ER-negative, PR-negative, HER2-negative) human breast cancer cells that have an intermediate response to chemotherapy [60] and express high levels of xCT [61].